Skip to content
Signal Bureau What’s happening · what the record shows

ctDNA

circulating tumor DNA — Fragments of tumor DNA in the blood, used for non-invasive cancer detection and monitoring.

Coverage of ctDNA is holding steady : 4 signals on the latest tracked day, down 86% from its three-week baseline of 28, across 3 domains (unchanged from a week ago). That makes it the #202 most-covered of the 348 concerns we track.

What’s changed

6 of the last 7 tracked days ran below the three-week baseline — a sustained cooling, not a one-day dip.

What the reporting says

It shows up alongside Colorectal Cancer (105), Lung Cancer (14), Immunotherapy (13), KRAS (11), Systematic Review (8), ASCO (12), Abstract (11), AI (10).

Two steps out: Braf (through Colorectal Cancer, 69 shared stories on the weaker link); Wang (through Colorectal Cancer, 63 shared stories on the weaker link); MSI-H (through Colorectal Cancer, 53 shared stories on the weaker link); Chen (through Colorectal Cancer, 45 shared stories on the weaker link).

Tracked since Mar 11, with coverage on 97 separate days — concentrated in Oncology and Pubmed Targeted.

Ask the engine about ctDNA + Track ctDNA for a daily read
Counts computed from our committed signal record (Jul 22 – Aug 27, 12 tracked days). Informational only — not financial, legal, or investment advice. Prediction-market prices are shown as a signal of what the crowd believes. Terms · Privacy · page rendered Aug 31, 4:32 PM PT